BACKGROUND: During the Fall of 2014, numerous children were hospitalized with asthma or respiratory distress related to Enterovirus D68 (EV-D68). A large proportion initially tested positive for rhinovirus. During this period our laboratory noted a cross-reactivity between EV-D68 and the rhinovirus component of the GenMark multiplex respiratory viral panel. Many other laboratories used assays not designed to distinguish these Picornoviridae. METHODS: To compare the presentation and outcomes of patients with rhinovirus and EV-D68, 103 GenMark rhinovirus positive nasopharyngeal swabs from hospitalized children were retested for EV-D68. RESULTS: EV-D68 positive patients versus EV-D68 negative patients were more likely to have a history of asthma (33.3% vs. 11.0%, P = 0.02) and to present with acute respiratory illness (66.7% vs. 40.2%, P = 0.048), especially status asthmaticus (47.6% vs. 2.4%, P < 0.001). On admission they had more wheezing, respiratory distress, and lower respiratory tract involvement, and were more likely to be treated with steroids and discharged home on asthma medications. Respiratory viral coinfection was less common in EV-D68 positive vs EV-D68 negative patients. In patients without a respiratory viral coinfection the overall findings were similar. CONCLUSION: Patients with EV-D68 versus rhinovirus were more likely to have a history of asthma, to present with status asthmaticus, to wheeze on admission, and to receive treatment with asthma medications in hospital and at discharge. The inability of common assays to distinguish EV-D68 from rhinoviruses raises the possibility that the role of EV-D68 as a viral trigger of asthma has been under appreciated. Pediatr Pulmonol. 2017;52:827-832.
BACKGROUND: During the Fall of 2014, numerous children were hospitalized with asthma or respiratory distress related to Enterovirus D68 (EV-D68). A large proportion initially tested positive for rhinovirus. During this period our laboratory noted a cross-reactivity between EV-D68 and the rhinovirus component of the GenMark multiplex respiratory viral panel. Many other laboratories used assays not designed to distinguish these Picornoviridae. METHODS: To compare the presentation and outcomes of patients with rhinovirus and EV-D68, 103 GenMark rhinovirus positive nasopharyngeal swabs from hospitalized children were retested for EV-D68. RESULTS:EV-D68 positive patients versus EV-D68 negative patients were more likely to have a history of asthma (33.3% vs. 11.0%, P = 0.02) and to present with acute respiratory illness (66.7% vs. 40.2%, P = 0.048), especially status asthmaticus (47.6% vs. 2.4%, P < 0.001). On admission they had more wheezing, respiratory distress, and lower respiratory tract involvement, and were more likely to be treated with steroids and discharged home on asthma medications. Respiratory viral coinfection was less common in EV-D68 positive vs EV-D68 negative patients. In patients without a respiratory viral coinfection the overall findings were similar. CONCLUSION:Patients with EV-D68 versus rhinovirus were more likely to have a history of asthma, to present with status asthmaticus, to wheeze on admission, and to receive treatment with asthma medications in hospital and at discharge. The inability of common assays to distinguish EV-D68 from rhinoviruses raises the possibility that the role of EV-D68 as a viral trigger of asthma has been under appreciated. Pediatr Pulmonol. 2017;52:827-832.
Authors: Ville Peltola; Matti Waris; Riikka Osterback; Petri Susi; Olli Ruuskanen; Timo Hyypiä Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Shane C McAllister; Mark R Schleiss; Sophie Arbefeville; Marie E Steiner; Ryan S Hanson; Catherine Pollock; Patricia Ferrieri Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240
Authors: Claire M Midgley; John T Watson; W Allan Nix; Aaron T Curns; Shannon L Rogers; Betty A Brown; Craig Conover; Samuel R Dominguez; Daniel R Feikin; Samantha Gray; Ferdaus Hassan; Stacey Hoferka; Mary Anne Jackson; Daniel Johnson; Eyal Leshem; Lisa Miller; Janell Bezdek Nichols; Ann-Christine Nyquist; Emily Obringer; Ajanta Patel; Megan Patel; Brian Rha; Eileen Schneider; Jennifer E Schuster; Rangaraj Selvarangan; Jane F Seward; George Turabelidze; M Steven Oberste; Mark A Pallansch; Susan I Gerber Journal: Lancet Respir Med Date: 2015-10-05 Impact factor: 30.700
Authors: Andrea Granados; Emma C Goodall; Kathy Luinstra; Marek Smieja; James Mahony Journal: Diagn Microbiol Infect Dis Date: 2015-05-07 Impact factor: 2.803
Authors: Claire M Midgley; Mary Anne Jackson; Rangaraj Selvarangan; George Turabelidze; Emily Obringer; Daniel Johnson; B Louise Giles; Ajanta Patel; Fredrick Echols; M Steven Oberste; W Allan Nix; John T Watson; Susan I Gerber Journal: MMWR Morb Mortal Wkly Rep Date: 2014-09-12 Impact factor: 17.586
Authors: Charu Rajput; Mingyuan Han; J Kelley Bentley; Jing Lei; Tomoko Ishikawa; Qian Wu; Joanna L Hinde; Amy P Callear; Terri L Stillwell; William T Jackson; Emily T Martin; Marc B Hershenson Journal: JCI Insight Date: 2018-08-23
Authors: Timothy J Savage; Jane Kuypers; Helen Y Chu; Miranda C Bradford; Anne Marie Buccat; Xuan Qin; Eileen J Klein; Keith R Jerome; Janet A Englund; Alpana Waghmare Journal: Influenza Other Respir Viruses Date: 2018-03-23 Impact factor: 4.380